Table 3 Distribution of cellular subpopulations in three areas of the liver using different antibodies.

	No	CD20	CD4	CD8	CD56	CD57	FasL	Bak
A. Central areas of portal tracts
PAH	14	2 *(93%)	3(79%)	1 (64%)	1 (100%)	1 (100%)	2 (79%)	1 (57%)
				2 (36%)				2 (43%)
AAH	10	2 (100%)	3 (80%)	1 (80%)	1 (100%)	1 (100%)	2 (90%)	1 (60%)
				2 (20%)				2 (40%)
HCV	5	2 (80%)	2 (100%)	2 (100%)	2 (60%)	1 (80%)	2 (80%)	2 (80%)
					3 (40%)
CL	10	2 (100%)	2 (80%)	2 (70%)	1 (90%)	0 (90%)	0 (60%)	1 (70%)
		2 (50%)					1 (20%)
B. Periportal areas
PAH	14	1* (86%)	1 (79%)	3 (100%)	1 (100%)	1 (100%)	2 (79%)	1 (57%)
								2 (43%)
AAH	10	1 (100%)	1 (80%)	3 (100%)	1 (100%)	1 (100%)	2 (90%)	1 (60%)
								2 (40%)
HCV	5	2 (80%)	2 (100%)	2 (100%)	2 (60%)	1 (80%)	2 (80%)	2 (80%)
					3 (40%)
CL	10	1 (100%)	2 (80%)	2 (70%)	1 (90%)	0 (90%)	1 (80%)	1 (70%)
C. Lobular areas
PAH	14	1*(86%)	1 (100%)	2 (64%)	1 (100%)	1 (100%)	1 (86%)	2 (93%)
				3 (36%)
AAH	10	1 (90%)	1 (100%)	2 (50%)	1 (100%)	1 (100%)	1 (80%)	2 (90%)
				3 (50%)
HCV	5	1 (80%)	2 (100%)	1 (80%)	1 (100%)	1 (80%)	2 (80%)	2 (80%)
CL	10	1 (100%)	2 (100%)	0 (100%)	1 (100%)	0 (90%)	0 (60%)	1 (70%)
							1 (20%)

Percentages of stained cells were independently analysed in different areas of the liver. *Scores found in at least 70% of biopsies analysed. The percentages of biopsies with each score (*) are indicated between brackets for each marker. As described in Methods the score was assessed on a five point scale: 0, 0–5%; 1, 5–20%; 2, 20–50%; 3, 50–80%; 4, 80–100%.

No, total number of patients.